Genetic polymorphisms in <i>CYP17</i>, <i>CYP3A4</i>, <i>CYP19A1</i>, <i>SRD5A2</i>, <i>IGF‐1</i>, and <i>IGFBP‐3</i> and prostate cancer risk in African‐American men: The Flint Men's Health Study

Abstract

These findings suggest that variation in or around CYP17 and/or IGF1 may be associated with prostate cancer development in the African-American population. Additional studies are needed to determine whether these polymorphisms are indeed associated with prostate cancer risk in African Americans.